0001209191-23-011665.txt : 20230222 0001209191-23-011665.hdr.sgml : 20230222 20230222163012 ACCESSION NUMBER: 0001209191-23-011665 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230217 FILED AS OF DATE: 20230222 DATE AS OF CHANGE: 20230222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arbuckle Stuart A CENTRAL INDEX KEY: 0001557290 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 23653599 MAIL ADDRESS: STREET 1: VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-17 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001557290 Arbuckle Stuart A C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, COO Common Stock 2023-02-17 4 F 0 4498 292.85 D 71107 D Common Stock 2023-02-21 4 S 0 21 291.01 D 71086 D Common Stock 2023-02-21 4 S 0 545 292.77 D 70541 D Common Stock 2023-02-21 4 S 0 1100 293.74 D 69441 D Common Stock 2023-02-21 4 S 0 736 294.58 D 68705 D Common Stock 140 I 401(k) Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $292.77 (range $292.25 to $293.07). Open market sales reported on this line occurred at a weighted average price of $293.74 (range $293.30 to $294.19). Open market sales reported on this line occurred at a weighted average price of $294.58 (range $294.36 to $294.96). /s/ Christiana Stevenson, Attorney-in-Fact 2023-02-22